ArticleVirologica Sinica2025
RNA and ChIP-sequencing analysis reveals SOX3 suppresses antiviral innate immunity through the AKT1-PTEN signaling axis.
Article in Virologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The transcription factor Sex-determining region Y-box protein 3 (SOX3) is well known for its critical roles in sex determination and cell differentiation; however, its function in antiviral innate immunity remains unexplored. This study uncovered how SOX3, induced by viral infections, modulates type I interferon (IFN-I) responses. RNA sequencing, quantitative PCR, and immunoblot analysis collectively revealed that SOX3 overexpression suppresses virus-induced interferon beta 1(IFN-β) promoter activation and significantly inhibits the expression of key antiviral interferon-stimulated genes (ISGs), including ISG15 and interferon induced protein with tetratricopeptide repeats 1 (IFIT1). Conversely, the knockdown of SOX3 enhanced IFN-β production and ISGs expression, confirming its role as a negative regulator of antiviral immunity. Mechanistically, chromatin immunoprecipitation sequencing (ChIP-seq) identified SOX3 binding specifically at the AKT serine/threonine kinase 1 (AKT1) locus. Further analysis demonstrated that SOX3 directly upregulates AKT1 expression, subsequently increasing phosphorylation and inactivation of the tumor suppressor phosphatase and tensin homolog (PTEN). Inactivation of PTEN inhibited interferon regulatory factor 3 (IRF3) nuclear translocation, leading to reduced IFN-β expression. Thus, our findings uncover a previously uncharacterized SOX3-AKT1-PTEN signaling axis in the regulation of antiviral innate immunity, providing new insights into immune evasion strategies and highlighting potential therapeutic targets to enhance antiviral responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.